Search results for: Precision Medicine
Filter search results
How long are patients WAITing for new treatments?
2 July 2026
…a medicine receiving marketing authorisation (MA), granted by the European Medicines Agency (EMA) or the relevant national authority, and achieving market access in individual countries. Market access is recorded at…
Forecasting the Challenges and Economics of Drug Development in 2022
9 July 2013
…this publication. 1. Health care will be radically transformed as “precision” medicines plug into the specific genetic makeup of both patients and diseases, paired with increasingly powerful and convenient diagnostics….
Meeting the Challenges of Drug Development in 2022: Summary of OHE’s 50th Anniversary Conference
11 October 2012
…practical application after approval as well, as personalised medicine (also called “stratified” or “precision” medicine) enhances the prospects for treating patients more effectively and safely. At the same time, however, many diseases with…
Lung Cancer’s Biggest Test: How Can We Mobilise NGS Testing to Transform Lung Cancer Care?
7 December 2023, 12:00am
…access to personalized medicines and combination medicines. She has expertise in market access and HTA, leading multiple submissions to NICE and the Scottish Medicines Consortium. Professor Mike Drummond | Professor…
International Comparison of Medicines Usage: Quantitative Analysis from a Swedish Perspective
1 May 2015
…different classes of medicines. In a majority of classes usage is below the two international averages. But while, for example, usage of cardiovascular medicines is low by international standards, use…
Global rare‑disease policy shifts: what are the implications for equitable access to orphan medicines?
1 March 2026
…as many orphan medicines compared with the EMA. One potential explanation for this divergence is the EU’s more restricted incentive offer, in addition to the European Medicines Agency (EMA) necessitating…
The Importance of Diversity of Supply in Rare Diseases Markets
23 January 2025
…RD medicine markets enhance healthcare system resilience and drive pharmaceutical innovation in areas of high unmet need and societal value. While medicine shortages are widely recognized as a critical issue…
OHE Develops New, Bottom-Up Model for Forecasting UK Medicines Expenditure
3 April 2013
Medicines account for less than 10% of total NHS expenditure in the UK. Because spending on medicines is easy to separate out, however, this sector continues to come under particular…
NICE at 25: Technology Appraisals – Faster Access to Modern Treatment?
1 May 2024
Introduction Since 1999, NICE has been assessing the cost and clinical effectiveness of medicines and health technologies for the NHS, providing guidance on their use by the NHS in England…